Stereotactic Radiosurgery for Brain Cancer
(SRS Trial)
Trial Summary
What is the purpose of this trial?
SRS dose escalation for brain metastases in radiation-naïve patients will establish true tolerable doses, which may exceed the current standard doses. This may lead to an improvement in local control, patient survival, and/or quality-of life.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Stereotactic Radiosurgery for brain cancer?
Research shows that Stereotactic Radiosurgery (SRS) is effective for treating brain metastases, improving outcomes and reducing side effects compared to whole-brain radiation therapy. It is used successfully for various conditions, including large brain metastases and multiple brain tumors, with studies indicating its effectiveness in controlling tumor growth and improving patient outcomes.12345
Is stereotactic radiosurgery generally safe for humans?
Stereotactic radiosurgery (SRS) and related treatments like CyberKnife and Gamma Knife are generally considered safe, with most incidents leading to little or no patient harm. Safety studies show that errors are often related to human performance and administrative issues, rather than the treatment itself, and efforts are ongoing to improve safety practices.678910
How is the treatment Stereotactic Radiosurgery (SRS) unique for brain cancer?
Stereotactic Radiosurgery (SRS) is unique because it delivers a high dose of focused radiation to a specific area in the brain in a single session, minimizing damage to surrounding healthy tissue. This makes it an effective option for treating brain metastases and other intracranial lesions, especially in areas that are difficult to reach with traditional surgery.111121314
Research Team
Robert Timmerman, MD
Principal Investigator
UTSW
Eligibility Criteria
This trial is for adults with non-hematopoietic cancer and up to 10 brain metastases, none larger than 3.0 cm or in the brain stem. Participants must not be pregnant, agree to use contraception, have an ECOG score of ≤2 or Karnofsky score ≥50, and can have had prior treatments except recent brain surgery or radiation.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive stereotactic radiosurgery (SRS) with dose escalation to determine maximal tolerated doses
Follow-up
Participants are monitored for safety, overall survival, time to progression, and local progression rate after treatment
Treatment Details
Interventions
- Stereotactic Radiosurgery
Stereotactic Radiosurgery is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Brain tumors
- Metastatic brain tumors
- Arteriovenous malformations (AVMs)
- Trigeminal neuralgia
- Acoustic neuromas
- Brain tumors
- Metastatic brain tumors
- Arteriovenous malformations (AVMs)
- Trigeminal neuralgia
- Acoustic neuromas
- Liver tumors
- Lung tumors
- Spinal cord tumors
- Brain tumors
- Metastatic brain tumors
- Arteriovenous malformations (AVMs)
- Trigeminal neuralgia
- Acoustic neuromas
- Brain tumors
- Metastatic brain tumors
- Arteriovenous malformations (AVMs)
- Trigeminal neuralgia
- Acoustic neuromas
- Brain tumors
- Metastatic brain tumors
- Arteriovenous malformations (AVMs)
- Trigeminal neuralgia
- Acoustic neuromas
- Brain tumors
- Metastatic brain tumors
- Arteriovenous malformations (AVMs)
- Trigeminal neuralgia
- Acoustic neuromas
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor